Get the app
Thomas Powles
GU medical oncologist from Barthes Cancer Institute in England and lead author of the NIAGARA trial. Expert in bladder cancer and immunotherapy.
Best podcasts with Thomas Powles
Ranked by the Snipd community
May 5, 2025
• 22min
Perioperative Durvalumab FDA Approval New Standard for Muscle Invasive Bladder Cancer
chevron_right
Dr. Thomas Powles, a GU medical oncologist from Barthes Cancer Institute and lead author of the NIAGARA trial, discusses the groundbreaking FDA approval of Durvalumab for muscle-invasive bladder cancer. The conversation delves into the trial's design, showcasing its promising survival rates compared to traditional treatments. Dr. Powles emphasizes the importance of immunotherapy in perioperative settings and the role of ctDNA in tailoring treatment strategies. Listeners gain insights into managing side effects and the evolving landscape of cancer care.
The AI-powered Podcast Player
Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
Get the app
